Cargando…

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome

Acute coronary syndrome and atrial fibrillation are both common and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions coexist, careful consideration is needed to determine the optimal antith...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bor, Wilbert, Gorog, Diana A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409267/ https://www.ncbi.nlm.nih.gov/pubmed/32605128 http://dx.doi.org/10.3390/jcm9072020

Ejemplares similares

Antithrombotic Strategies in Patients with Atrial Fibrillation and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
por: De Luca, Leonardo, et al.
Publicado: (2022)

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
por: Moustafa, Abdelmoniem, et al.
Publicado: (2019)

Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
por: Wei, Lili, et al.
Publicado: (2020)

Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
por: Kwak, Soongu, et al.
Publicado: (2019)

Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes
por: Bonanad, Clara, et al.
Publicado: (2022)

Adding to the evidence or to the confusion: dual antithrombotic therapy in chronic coronary syndrome and atrial fibrillation
por: Kany, Shinwan, et al.
Publicado: (2021)

Impact of Antithrombotic Therapy in Atrial Fibrillation on the Presentation of Coronary Artery Disease
por: Chan, Pak Hei, et al.
Publicado: (2015)

Efficacy and Safety of Antithrombotic Therapy With Oral Anticoagulants in Real-World Elderly Patients With Acute Coronary Syndrome and Atrial Fibrillation
por: Wu, Yangxun, et al.
Publicado: (2022)

The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
por: Liu, Zhengwang, et al.
Publicado: (2022)

Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?
por: Limbruno, Ugo, et al.
Publicado: (2020)

Experiences of Patients With Atrial Fibrillation With Combination Antithrombotic Therapy Post–Percutaneous Coronary Intervention
por: Poirier, Caylie M., et al.
Publicado: (2023)

Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update
por: Zhao, Shujuan, et al.
Publicado: (2021)

Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice
por: Sabir, Ian N, et al.
Publicado: (2013)

Updated overview of evidence on optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutanous coronary intervention
por: Koziński, Marek, et al.
Publicado: (2020)

The sunset of triple antithrombotic therapy for atrial fibrillation patients
por: Capranzano, Piera
Publicado: (2019)

Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy
por: Baturina, Olga, et al.
Publicado: (2023)

Retracted: The Value of Rivaroxaban Combined with Ticagrelor in Antithrombotic Therapy after PCI in Patients with Nonvalvular Atrial Fibrillation with Acute Coronary Syndrome
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention
por: Lu, Wenbin, et al.
Publicado: (2021)

Managing antithrombotic treatment in a patient with atrial fibrillation and coronary stent with transient neurological symptoms in cerebral amyloid angiopathy
por: Ravn, Julie, et al.
Publicado: (2022)

ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes
por: De Luca, Leonardo, et al.
Publicado: (2022)

Antithrombotic treatment in atrial fibrillation patients needing percutaneous coronary intervention
por: Huisman, M. V.
Publicado: (2021)

The WOEST 2 registry: A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention
por: de Veer, A. J. W. M., et al.
Publicado: (2022)

Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study
por: De Luca, Leonardo, et al.
Publicado: (2020)

Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much!
por: Jacobs, M. S., et al.
Publicado: (2018)

Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation
por: Falco, Luigi, et al.
Publicado: (2023)

Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome
por: Towashiraporn, Korakoth, et al.
Publicado: (2022)

Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention
por: Park, Jiesuck, et al.
Publicado: (2020)

Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease
por: Lee, Kuo-Hua, et al.
Publicado: (2021)

Net clinical benefit of antithrombotic therapy for atrial fibrillation patients with stable coronary artery disease
por: Lee, So-Ryoung, et al.
Publicado: (2022)

Post‐Intracranial Hemorrhage Antithrombotic Therapy in Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2022)

Critical Appraisal of Guidelines for Antithrombotic Therapy in Atrial Fibrillation Post-Percutaneous Coronary Intervention
por: Fan, Yongqiang, et al.
Publicado: (2022)

New Antithrombotic Drugs in Acute Coronary Syndrome
por: Zwart, Bastiaan, et al.
Publicado: (2020)

Update on Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
por: Abcede, Hermelinda G., et al.
Publicado: (2010)

Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation After Coronary Stent Implantation
por: Jang, Sung-Won, et al.
Publicado: (2011)

Optimal antithrombotic therapy after transcatheter aortic valve replacement in patients with atrial fibrillation
por: Zeng, Qingchun, et al.
Publicado: (2020)

Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?
por: Guo, Yutao, et al.
Publicado: (2010)

A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series
por: Giubilato, Simona, et al.
Publicado: (2022)

Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis
por: Guo, Wenqin, et al.
Publicado: (2020)

Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain
por: Rivolo, Simone, et al.
Publicado: (2021)

Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
por: Bachorski, Witold, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qkcddvpana33n2si8f1seej0lu